FINGOLIMOD

Course overview

FINGOLIMOD IS THE FIRST ORAL DISEASE-MODIFYING AGENT APPROVED BY THE US FOOD AND DRUG ADMINISTRATION (FDA) FOR TREATING MULTIPLE SCLEROSIS. THE DRUG EFFECTIVELY MANAGES RELAPSING AND REMITTING MULTIPLE SCLEROSIS (RRMS), CLINICALLY ISOLATED SYNDROMES, AND ACTIVE SECONDARY PROGRESSIVE DISEASE. THE PRIMARY FUNCTION OF FINGOLIMOD IS TO INHIBIT LYMPHOCYTE MIGRATION INTO PERIPHERAL CIRCULATION BY ANTAGONIZING SPHINGOSINE-1-PHOSPHATE RECEPTOR-1 (S1PR1) FUNCTIONS, THEREBY REDUCING THE BODY'S INFLAMMATORY RESPONSE. ADDITIONALLY, FINGOLIMOD MODULATES VARIOUS IMMUNE SYSTEM ACTIVITIES, INCLUDING T-CELL CENTRAL AND PERIPHERAL TOLERANCE, AUTOREACTIVITY, T-CELL DIFFERENTIATION, AND REGULATION OF THE INNATE IMMUNE SYSTEM. HOWEVER, CONCERNS EXIST REGARDING FINGOLIMOD'S IMPACT ON THE CARDIOVASCULAR SYSTEM, PARTICULARLY CARDIAC CHRONOTROPY, WHICH MAY ELEVATE MORTALITY RISK.THIS ACTIVITY REVIEWS THE INDICATIONS, MECHANISM OF ACTION, CONTRAINDICATIONS, POTENTIAL INTERACTIONS, AND NECESSARY MONITORING PARAMETERS FOR FINGOLIMOD. THIS ACTIVITY ALSO EMPHASIZES THE IMPORTANCE OF AN INTERDISCIPLINARY HEALTHCARE TEAM IN OPTIMIZING CARE FOR PATIENTS WITH RRMS UNDERGOING FINGOLIMOD TREATMENT, THEREBY AIMING TO ENHANCE PATIENT OUTCOMES THROUGH COORDINATED CARE.